Medical Education Library

Once-weekly Glucagon-like Peptide-1 Receptor Agonists

This supplement is supported by funding from Novo Nordisk Inc.


Click Here to Read the Supplement

This supplement provides an overview of the role of once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in type 2 diabetes (T2D).

Topics include:

  • Burden of illness in patients with T2D
  • Pharmacokinetic properties and the mode and mechanism of action of GLP-1 RAs
  • Safety and clinical efficacy of GLP-1 RAs
  • Implications of cardiovascular outcomes trials in T2D

Click Here to Read the Supplement

Next Article: